Apogee secures up to $1.3B non-dilutive financing from Blackstone for zumilokibart

Apogee Therapeutics, Inc.

$100M upfront received; additional $100M upon Phase 3 enrollment, $200M on positive Phase 3 data.
Up to $400M more at FDA approval ($150M at Apogee's option); total synthetic royalty up to $800M.
Low-to-mid single digit tiered royalties for 15 years on worldwide net sales; no royalties above $8B.
Up to $500M senior corporate debt available at mutual consent with Blackstone.
Company removes cash runway guidance; combined with $1.3B current cash positions for self-sustainability.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apogee Therapeutics, Inc. entered into Revenue Share Agreement with Annapurna Aggregator L.P., an affiliate of funds managed by Blackstone Life Sciences valued at $100.0 million upfront payment (effective 2026-05-26).

Action: entry
Agreement: asset purchase
Counterparty: Annapurna Aggregator L.P., an affiliate of funds managed by Blackstone Life Sciences
Value: $100.0 million upfront payment
Effective: 2026-05-26

Exact text from the filing

On May 26, 2026 (the “Effective Date”), Apogee Therapeutics, Inc. (the “Company”) entered into a revenue participation right purchase and sale agreement (the “Revenue Share Agreement”) with Annapurna Aggregator L.P., an affiliate of funds managed by Blackstone Life Sciences (“BXLS”).

View on SEC.gov

Browse all material agreements →

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-066575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.